Statin use and risk of pancreatic cancer: Results from a large, clinic-based case-control study

Cancer

Volumn 121, Issue 8, 2015, Pages 1287-1294

  Walker, Evan J ^a   Ko, Andrew H ^a   Holly, Elizabeth A ^b   Bracci, Paige M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 hydroxy 3 methyl glutaryl coenzyme A (HMG CoA) reductase inhibitors; cancer risk; case control; pancreatic adenocarcinoma; statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SEX RATIO; TREATMENT DURATION; UNITED STATES; VERY ELDERLY; YOUNG ADULT; HYPERCHOLESTEROLEMIA; PANCREATIC NEOPLASMS; QUESTIONNAIRE; SEX DIFFERENCE; STATISTICAL MODEL; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SEX FACTORS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84927087932     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29256     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Ryan DP, Hong TS, Bardeesy N,. Pancreatic adenocarcinoma. N Engl J Med. 2014; 371: 1039-1049.
3. Lowenfels AB, Maisonneuve P,. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006; 20: 197-209.
4. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 1: CD004816.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63 (pt B): 2889-2934.
6. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM,. Statins and cancer prevention. Nat Rev Cancer. 2005; 5: 930-942.
7. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ,. The risk of cancer in users of statins. J Clin Oncol. 2004; 22: 2388-2394.
8. Nielsen SF, Nordestgaard BG, Bojesen SE,. Statin use and reduced cancer-related mortality. N Engl J Med. 2012; 367: 1792-1802.
9. Nguyen DM, Richardson P, El-Serag HB,. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010; 138: 2260-2266.
10. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352: 2184-2192.
11. Shi M, Zheng H, Nie B, Gong W, Cui X,. Statin use and risk of liver cancer: an update meta-analysis. BMJ Open. 2014; 4: e005399.
12. Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med. 2001; 10: 971-981.
13. Marelli C, Gunnarsson C, Ross S, et al. Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol. 2011; 58: 530-537.
14. Olsen JH, Johansen C, Sorensen HT, et al. Lipid-lowering medication and risk of cancer. J Clin Epidemiol. 1999; 52: 167-169.
15. Sato S, Ajiki W, Kobayashi T, Awata N,; PCS Study Group. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol. 2006; 16: 201-206.
16. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 287: 3215-3222.
17. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004; 364: 771-777.
18. Bradley MC, Hughes CM, Cantwell MM, Murray LJ,. Statins and pancreatic cancer risk: a nested case-control study. Cancer Causes Control. 2010; 21: 2093-2100.
19. Carey FJ, Little MW, Pugh TF, et al. The differential effects of statins on the risk of developing pancreatic cancer: a case-control study in two centres in the United Kingdom. Dig Dis Sci. 2013; 58: 3308-3312.
20. Chiu HF, Chang CC, Ho SC, Wu TN, Yang CY,. Statin use and the risk of pancreatic cancer: a population-based case-control study. Pancreas. 2011; 40: 669-672.
21. Coogan PF, Rosenberg L, Strom BL,. Statin use and the risk of 10 cancers. Epidemiology. 2007; 18: 213-219.
22. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA,. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf. 2008; 17: 27-36.
23. Haukka J, Sankila R, Klaukka T, et al. Incidence of cancer and statin usage-record linkage study. Int J Cancer. 2010; 126: 279-284.
24. Jacobs EJ, Newton CC, Thun MJ, Gapstur SM,. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011; 71: 1763-1771.
25. Kaye JA, Jick H,. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004; 90: 635-637.
26. Khurana V, Sheth A, Caldito G, Barkin JS,. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas. 2007; 34: 260-265.
27. Duncan RE, El-Sohemy A, Archer MC,. Statins and cancer development. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1897-1898.
28. Gbelcova H, Lenicek M, Zelenka J, et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer. 2008; 122: 1214-1221.
29. Schachter M,. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005; 19: 117-125.
30. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol. 2000; 20: 139-148.
31. Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, Thapar N,. Farnesylated proteins and cell cycle progression. J Cell Biochem Suppl. 2001; 37: 64-70.
32. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M,. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53: 549-554.
33. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801-1806.
34. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB,. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res. 2002; 91: 143-150.
35. Weis M, Heeschen C, Glassford AJ, Cooke JP,. Statins have biphasic effects on angiogenesis. Circulation. 2002; 105: 739-745.
36. Kusama T, Mukai M, Iwasaki T, et al. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology. 2002; 122: 308-317.
37. Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res. 2001; 61: 4885-4891.
38. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC,. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 1997; 11: 463-475.
39. Dulak J, Jozkowicz A,. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005; 5: 579-594.
40. Desai CS, Martin SS, Blumenthal RS,. Non-cardiovascular effects associated with statins. BMJ. 2014; 349: g3743.
41. Dale KM, Coleman CI, Shah SA, Patel AA, Kluger J, White CM,. Impact of gender on statin efficacy. Curr Med Res Opin. 2007; 23: 565-574.
42. Gutierrez J, Ramirez G, Rundek T, Sacco RL,. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012; 172: 909-919.
43. Cui X, Xie Y, Chen M, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012; 23: 1099-1111.
44. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM,. Statins and cancer risk: a meta-analysis. JAMA. 2006; 295: 74-80.
45. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2011), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission.
46. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007; 166: 348-354.